Effects of acipimox and cholestyramine on serum lipoproteins, non-cholesterol sterols and cholesterol absorption and elimination.
The hypolipidaemic and metabolic effects of cholestyramine combined with acipimox or placebo have been evaluated in a double-blind ninety-day study in 18 patients with xanthomatous familial hypercholesterolaemia. Serum LDL-cholesterol was reduced by 35% in the cholestyramine group and 39% in the acipimoxcholestyramine group. The latter treatment increased the HDL-cholesterol level. Serum VLDL-cholesterol and triglyceride concentrations were unchanged. Cholesterol absorption efficiency was significantly reduced, and bile acid synthesis and faecal cholesterol elimination in both groups were increased. The metabolic changes were similar in the two treatment groups, but the increase in faecal neutral sterol excretion was significant only when acipimox was added. The serum cholesterol precursor sterol contents were similarly increased during the two treatments, indicating enhancement of endogenous cholesterol synthesis. The decrease in cholesterol absorption and the increase in neutral sterol excretion were more pronounced in subjects with greater than 30% than in those with less than 30% reduction in LDL-cholesterol. The changes in serum total and LDL-cholesterol levels and cholesterol metabolism were not related to apoE phenotype, but the increase in HDL-cholesterol was higher in E4 then in E3 subjects.
Gylling
H
H
Second Department of Medicine, University of Helsinki, Finland.
Vanhanen
H
H
Miettinen
T A
TA
D000328:Adult; D001057:Apolipoproteins E / Q000097:blood; D002784:Cholesterol / Q000097:blood* / Q000493:pharmacokinetics; D008078:Cholesterol, LDL / Q000097:blood; D002792:Cholestyramine Resin / Q000494:pharmacology*; D004311:Double-Blind Method; D005243:Feces / Q000032:analysis; D005260:Female; D006801:Humans; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D007408:Intestinal Absorption; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood*; D008297:Male; D010641:Phenotype; D011719:Pyrazines / Q000494:pharmacology*; D013185:Squalene / Q000097:blood; D013261:Sterols / Q000097:blood* / Q000493:pharmacokinetics
D001057:Apolipoproteins E; D008078:Cholesterol, LDL; D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D011719:Pyrazines; D013261:Sterols; D002792:Cholestyramine Resin; D013185:Squalene; D002784:Cholesterol; C027696:acipimox